Researchers have discovered a promising new weight loss treatment that combines cagrilintide and semaglutide, two medications used to treat type 2 diabetes. The study found that adults with obesity who received this combination treatment lost more weight than those who took placebos.
In the REDEFINE trials, participants were given either cagrilintide-semaglutide or a placebo over a period of 68 weeks. Those who received the treatment lost an average of 20.4% of their body weight, compared to 3% for those on the placebo. The study also found that patients without diabetes who took the treatment were more likely to achieve significant weight loss.
The researchers say that this new combination therapy has shown promise in expanding treatment options for people with obesity and type 2 diabetes. While more research is needed, the results are encouraging and could lead to a new standard of care for weight management.
Cagrilintide, an amylin analogue, works by binding to receptors in the brain that regulate food intake and body weight. When combined with semaglutide, a GLP-1 receptor agonist, it may help reduce hunger and increase feelings of fullness, leading to weight loss.
The study’s findings were published simultaneously in the New England Journal of Medicine and have been hailed as an important step forward in expanding treatment options for people with obesity and type 2 diabetes.
Source: https://www.medpagetoday.com/meetingcoverage/ada/116188